Summary: New research explains how increased intraocular pressure can deform tiny blood vessels in the optic nerve region and impair oxygen delivery, potentially accelerating glaucoma — a major cause of irreversible vision loss. Using advanced three-dimensional modeling and fluorescent tracers, researchers observed that even modest pressure elevations can reduce blood flow to critical tissues at the back of the eye.
This reduced oxygen supply (hypoxia) can harm retinal and optic nerve cells and may continue to cause damage even when eye pressure is lowered with current treatments. The study suggests that measuring blood flow and oxygenation could enable earlier detection of glaucoma by revealing vascular changes before permanent visual loss occurs.
Key Facts:
- Vascular impact: Elevated intraocular pressure can physically deform vessels in the optic nerve head, lowering oxygen delivery to neural tissue.
- Early detection potential: Changes in blood flow and oxygenation may serve as early indicators of glaucoma before symptoms and irreversible damage appear.
- Treatment limitations: Lowering eye pressure is currently the primary therapy, but some patients continue to lose vision despite controlled pressure, highlighting the need for new approaches.
Source: University of Mississippi
Overview
Glaucoma, which damages the optic nerve and can cause permanent vision loss, is a leading cause of blindness worldwide. Often called the “silent thief of sight,” glaucoma may progress without noticeable symptoms until substantial and irreversible damage has occurred. New collaborative research from the University of Mississippi and the University of Pittsburgh explores how ocular hypertension — sustained elevation of pressure inside the eye — affects blood circulation and oxygen delivery in the optic nerve region.
Yi Hua, a biomedical engineering professor at the University of Mississippi, led the study in partnership with investigators at the University of Pittsburgh. The team combined high-resolution imaging, fluorescent dye tracing, and three-dimensional computational models to visualize how different levels of intraocular pressure distort microvascular geometry and change oxygen distribution within the lamina cribrosa — the porous, mesh-like structure at the optic nerve head.
“We aimed to understand how changes in intraocular pressure deform blood vessels in the eye,” Hua said. “A clearer mechanical and physiological picture can guide drug delivery strategies and therapies targeted at restoring or preserving blood flow in the back of the eye, ultimately slowing glaucoma progression.”
Pressure in the eye rises when aqueous humor, the clear fluid that nourishes ocular tissues, does not drain properly. When pressure builds, it compresses structures such as the lamina cribrosa and can constrict the small vessels that supply the optic nerve. Reduced blood flow causes local hypoxia, which deprives nerve cells of oxygen and can lead to cell death and permanent vision loss.
The researchers report that even mild, sustained increases in intraocular pressure were enough to change vessel shape and reduce oxygen delivery. In simulations of extreme pressure, roughly 30% of the lamina cribrosa tissue experienced hypoxia. Short, transient pressure spikes (for example, brief rubbing of the eyes) are usually tolerated, but chronic pressure elevation over weeks, months, or years can produce irreversible damage.
“The eye can tolerate brief pressure changes,” noted Ian Sigal, associate professor of ophthalmology and bioengineering at the University of Pittsburgh. “However, chronic elevation can cause lasting damage that cannot be recovered. Detecting those vascular and oxygenation changes early is essential to prevent sight loss.”
Yuankai Lu, a postdoctoral researcher and co-author, emphasized the value of combining imaging with mechanical modeling to move beyond purely statistical associations. “Many prior studies show a correlation between high eye pressure and glaucoma, but the mechanical mechanisms were less clear,” Lu said. “Linking imaging data to 3D models gave us a more complete picture of how blood flow and oxygen distribution are altered by pressure.”
Current treatments for elevated intraocular pressure are most effective when glaucoma is diagnosed early during routine eye exams, especially for people with risk factors such as diabetes, high blood pressure, family history of glaucoma, or certain racial and ethnic backgrounds that are associated with higher disease prevalence. The research team hopes their findings will raise awareness about the importance of monitoring eye pressure and vascular health, and will spur development of therapies that protect blood supply to the optic nerve.
Funding: This work was supported by the National Institutes of Health under grant numbers R01-EY023966, R01-EY031708, R01-HD083383, P30-EY008098 and T32-EY017271.
About this glaucoma and visual neuroscience research news
Author: Clara Turnage
Source: University of Mississippi
Contact: Clara Turnage, University of Mississippi
Image credit: Neuroscience News
Original Research (open access): “Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study” by Yi Hua et al., Ophthalmology Science
Abstract
Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study
Purpose
To evaluate whether use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with the risk of primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG) in people with type 2 diabetes mellitus (T2DM).
Design
Retrospective, population-based cohort study.
Subjects
The analysis included 582,710 patients with T2DM treated between 2008 and 2021, comparing those prescribed DPP4i (exposure group) with patients receiving non-DPP4i antidiabetic medications (control group).
Methods
Patients were matched one-to-one using propensity scores based on demographic and clinical characteristics. Cox proportional hazards models estimated adjusted hazard ratios for POAG and NTG, controlling for age, sex, comorbidities, and concurrent antidiabetic therapies.
Main Outcome Measures
Incidence of primary open-angle glaucoma and normal-tension glaucoma.
Results
Use of DPP4i was associated with a significantly lower risk of POAG (adjusted hazard ratio [aHR], 0.53; 95% CI, 0.50–0.56) and NTG (aHR, 0.55; 95% CI, 0.50–0.62) compared with users of first-generation diabetes medications. Subgroup analyses showed consistent risk reductions across age groups (18–39: aHR 0.56; 40–64: aHR 0.52; ≥65: aHR 0.51) and among patients with and without diabetes-related complications (including diabetic retinopathy, kidney disease, and neuropathy), with statistically significant differences (p < 0.001). Cumulative incidence curves indicated a sustained lower risk for DPP4i users over the study period (log-rank p < 0.001).
Conclusions
In this large nationwide cohort, exposure to DPP4i was associated with a decreased risk of developing POAG and NTG compared with first-generation antidiabetic medications. Further investigation is warranted to clarify underlying mechanisms and potential implications for glaucoma prevention and management.